Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

EARLY_PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inhaled nitric oxide in patients with pulmonic valve insufficiency.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement

NCT01717209

Heart Failure

COMPLETED PHASE4

Inhaled Nitrite in Subjects With Pulmonary Hypertension

NCT01431313

Pulmonary Hypertension Heart Failure, Diastolic

COMPLETED PHASE2

Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide

NCT02170519

Pulmonary Hypertension

TERMINATED PHASE4

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526

Pulmonary Hypertension

TERMINATED PHASE4

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT03015402

Pulmonary Hypertension Secondary Heart Failure

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pulmonic valve insufficiency (PI) is a well-defined problem after primary surgical repair of Tetralogy of Fallot (TOF). Though well-tolerated for years, long-term PI can lead to structural changes in the right ventricle, the sequelae of which include right heart failure, arrhythmia, and sudden cardiac death. The only current treatment for severe symptomatic PI is pulmonic valve replacement. We hypothesize that inhaled nitric oxide (iNO), a selective pulmonary vasodilator, can acutely decrease PI as assessed by cardiac magnetic resonance imaging (CMR). Methods: 22 consecutive patients with PI in the setting of corrected TOF or post pulmonic valve balloon valvuloplasty will undergo a clinically indicated CMR. Nitric oxide gas will be delivered via facemask through a specialized delivery device at 40ppm. After 5 minutes, flow velocity mapping and gradient echo sequences will be repeated to assess pulmonary regurgitant fraction, right ventricular volumes, and ejection fraction. Nitric oxide will be discontinued after acquisition of the last picture. Wilcoxon rank-sum for paired data will be used to assess effect of intervention. Significance: If decreasing pulmonary vascular resistance decreases PI, medical therapy with long-acting pulmonary vasodilators may be an attractive therapeutic option with the goal of delaying or even obviating pulmonic valve replacement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

iNO administered

iNO administered at 40 ppm via a non-rebreather mask

Group Type EXPERIMENTAL

iNO administered

Intervention Type DRUG

iNO at 40 ppm through a non-rebreather mask for 5 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

iNO administered

iNO at 40 ppm through a non-rebreather mask for 5 minutes

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Nitric Oxide

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Known pulmonary insufficiency status
* Previous Tetralogy of Fallot repair or balloon valvuloplasty/surgical valvotomy for pulmonary stenosis
* Clinically indicated cardiac magnetic resonance imaging study

Exclusion Criteria

* Enrollment in another clinical trial
* Age less then 18 years
* Inability to provide informed consent
* Institutionalized individual
* Pregnant or lactating
* Serious claustrophobia
* Pacemaker/ICD
* Aneurysm clips
* Internal hardware
* Severe obesity (\>350lbs)
* Residual ventricular septal defect
* History of methemoglobinemia
* History of blood dyscrasias
* Acute pulmonary infection
* Pulmonary edema
* Hypersensitivity to nitric oxide or any of its components
* Left ventricle dysfunction (EF\<40%)
* Concurrent use of nitroglycerin or prilocaine

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No